{Reference Type}: Journal Article
{Title}: Red Blood Cell Membrane-Coated Nanoparticles Enable Incompatible Blood Transfusions.
{Author}: Yang X;Chen M;Weng C;Zhuge D;Jin F;Xiao Y;Tian D;Yin Q;Li L;Zhang X;Shi G;Lu X;Yan L;Wang L;Wen B;Zhao Y;Lin J;Wang F;Zhang W;Chen Y;
{Journal}: Adv Sci (Weinh)
{Volume}: 11
{Issue}: 29
{Year}: 2024 Aug 5
{Factor}: 17.521
{DOI}: 10.1002/advs.202310230
{Abstract}: Blood transfusions save lives and improve health every day. Despite the matching of blood types being stricter than it ever has been, emergency transfusions among incompatible blood types are still inevitable in the clinic when there is a lack of acceptable blood types for recipients. Here to overcome this, a counter measure nanoplatform consisting of a polymeric core coated by a red blood cell (RBC) membrane is developed. With A-type or B-type RBC membrane camouflaging, the nanoplatform is capable of specifically capturing anti-A or anti-B IgM antibodies within B-type or A-type whole blood, thereby decreasing the corresponding IgM antibody levels and then allowing the incompatible blood transfusions. In addition to IgM, the anti-RBC IgG antibody in a passive immunization murine model can likewise be neutralized by this nanoplatform, leading to prolonged circulation time of incompatible donor RBCs. Noteworthily, nanoplatform made by expired RBCs (>42 days stored hypothermically) and then subjected to lyophilization does not impair their effect on antibody neutralization. Most importantly, antibody-captured RBC-NP do not exacerbate the risk of inflammation, complement activation, and coagulopathy in an acute hemorrhagic shock murine model. Overall, this biomimetic nanoplatform can safely neutralize the antibody to enable incompatible blood transfusion.